{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:19:43Z","timestamp":1763018383378,"version":"3.45.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":568,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["20182MFDS443","CSTI571XKR25T"],"award-info":[{"award-number":["20182MFDS443","CSTI571XKR25T"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jtct.2021.07.019","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T19:30:35Z","timestamp":1627155035000},"page":"925.e1-925.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic\/Fibrotic Type Chronic Graft-versus-Host Disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Jung Yoon","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyery","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jo","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoon","family":"Kook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Yul","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Taek","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoung Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.07.019_bib0001","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.019_bib0002","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200006223422501","article-title":"Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources","volume":"342","author":"Rocha","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.07.019_bib0003","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2133.2011.10360.x","article-title":"German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD","volume":"165","author":"Marks","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtct.2021.07.019_bib0005","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood-2018-04-785899","article-title":"How I treat refractory chronic graft-versus-host disease","volume":"133","author":"Sarantopoulos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0006","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/09031936.00152106","article-title":"Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis","volume":"29","author":"Chaudhary","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtct.2021.07.019_bib0007","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0008","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2009-02-204750","article-title":"Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease","volume":"114","author":"Magro","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0009","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0010","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/petr.12004","article-title":"Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD","volume":"16","author":"Kim","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2021.07.019_bib0011","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.019_bib0012","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report","volume":"12","author":"Pavletic","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.019_bib0013","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.019_bib0014","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V97.5.1196","article-title":"How I treat chronic graft-versus-host disease","volume":"97","author":"Vogelsang","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","article-title":"Diagnosis and management of chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.07.019_bib0016","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2040620713489842","article-title":"Treatment and management of graft-versus-host disease: improving response and survival","volume":"4","author":"Garnett","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtct.2021.07.019_bib0017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V100.1.48","article-title":"Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone","volume":"100","author":"Koc","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0018","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.07.019_bib0019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation","volume":"22","author":"Arai","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2021.07.019_bib0020","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2011-03-341693","article-title":"A phase 1 study of imatinib for corticosteroid-dependent\/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies","volume":"118","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0021","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2013-05-494278","article-title":"Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD","volume":"122","author":"Olivieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0022","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bmt.1703633","article-title":"Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients","volume":"30","author":"Baudard","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.019_bib0023","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00277-005-1070-0","article-title":"Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease","volume":"84","author":"Krejci","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.07.019_bib0024","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.019_bib0025","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.019_bib0026","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/imt-2017-0156","article-title":"Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials","volume":"10","author":"Jagasia","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtct.2021.07.019_bib0027","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.07.019_bib0028","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","article-title":"Ruxolitinib as salvage therapy for chronic graft-versus-host disease","volume":"25","author":"Modi","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721011027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721011027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:07:02Z","timestamp":1763003222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721011027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2666636721011027"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.07.019","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic\/Fibrotic Type Chronic Graft-versus-Host Disease","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}